Amarin Corporation PLC (NASDAQ:AMRN)
| 5.02 Delayed Data As of Oct 22 |  +0.01 / +0.20%Today’s Change | 3.84 Today|||52-Week Range 9.25 | +2.66% Year-to-Date |
Latest AMRN News | Press Releases
| All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy Oct 11 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 5.01 |
| Today’s open | 5.00 |
| Day’s range | 4.93 - 5.02 |
| Volume | 114,974 |
| Average volume (3 months) | 3,326,888 |
| Market cap | $2.0B |
Data as of 4:49pm ET, 10/22/2021
Growth & Valuation
| Earnings growth (last year) | +28.46% |
| Earnings growth (this year) | +35.56% |
| Earnings growth (next 5 years) | +36.10% |
| Revenue growth (last year) | +43.40% |
| P/E ratio | 502.0 |
| Price/Sales | 3.02 |
| Price/Book | 3.13 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| --Oxford BioMedica PLC | -0.10 | -0.54% |
| AVXLAnavex Life Sciences... | -0.15 | -0.83% |
| FGENFibroGen Inc | +0.26 | +2.45% |
| DBVTDBV Technologies SA | -0.06 | -1.08% |
Data as of 3:59pm ET, 10/22/2021
Financials
| Next reporting date | November 3, 2021 |
| EPS forecast (this quarter) | -$0.04 |
| Annual revenue (last year) | $618.8M |
| Annual profit (last year) | -$18.1M |
| Net profit margin | -2.93% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters Dublin, Dublin |
Forecasts
